The gene PRG2, encoding the proform of eosinophil major basic protein (proMBP), is one of the most highly expressed genes during human pregnancy, and low proMBP levels predict Down syndrome and poor pregnancy outcome. Reminiscent of a magnet, the primary structure of proMBP is extremely charge polarized, consisting of an N-terminal acidic propiece followed by a highly basic MBP domain in the C-terminal. Many tissues synthesize and secrete full-length proMBP, but only distinct cell types of the immune system process and store mature MBP in intracellular granules. MBP is released upon degranulation of eosinophil leukocytes and is toxic to bacteria, parasites, and mammalian cells. In contrast, proMBP is apparently nontoxic and functions in the inhibition of proteolysis and prohormone conversion. Recent research has revealed the complexity of proMBP biology and shed light on the process of MBP generation. ProMBP specifically forms disulfide-mediated, covalent complexes with the metzincin metalloproteinase pregnancy-associated plasma protein A (PAPPA) and the prohormone angiotensinogen (AGT). In both processes, PAPPA and AGT have reduced biological activity in the resulting complexes. In addition, proMBP is a component of high-molecular-weight AGT and, therefore, is potentially involved in the development of preeclampsia and in pregnancy-induced hypertension.
INTRODUCTION
The proteolytically processed eosinophil major basic protein (MBP; also known as PRG2) was first described as the major constituent of the crystalloid core of the eosinophil leukocyte granules. MBP is highly basic and toxic to both mammalian cells and parasites, and it functions in the defense against invading parasites. Hence, it was a surprise when a protein immunochemically similar to MBP was detected in the placenta and in the circulation of pregnant women [1, 2] . The protein was of higher molecular weight compared to MBP isolated from the eosinophil granules and was suggested to be disulfide bonded to other proteins [3] . Later, this protein was identified as the unprocessed form (the proform of eosinophil MBP [proMBP] ) in disulfide-linked complexes with the metalloproteinase pregnancy-associated plasma protein A (PAPPA) [4] and the prohormone angiotensinogen (AGT) [5] .
The Proform of Eosinophil MBP
Major basic protein purified from the granules of eosinophil leukocytes has a molecular weight of 13.8 kDa and is highly basic (pI ¼ 10.9). However, analysis of an isolated cDNA clone revealed that MBP is synthesized as a precursor form of 222 residues, including a 16-residue signal peptide and a highly acidic propiece of 89 residues (Fig. 1) [6] . The propiece of human proMBP isolated from pregnancy serum is extensively and heterogeneously glycosylated with an average carbohydrate content of 38% (w/w), including several O-linked and one N-linked glycosylation. In addition, the propiece is substituted with a glycosaminoglycan (GAG) of the heparan sulfate type [7] . Based on the amino acid sequence, the pI of the propiece was calculated to be 4.0 [6] , but the GAG chain most likely contributes further to its acidity. Mature MBP is generated in the bone marrow by maturing eosinophils, and the propiece is believed to mask the cytotoxicity of MBP before proteolytic processing upon granule condensation [8] . In proMBP, the propiece is chained to the MBP domain by three intramolecular disulfide bonds, and these must consequently be disrupted by an unknown mechanism in maturing eosinophils in the bone marrow for the formation of mature MBP [9] .
MBP Is an Unusual C-Type Lectin
It is unclear how MBP exerts its cytotoxic and cytostimulatory functions, but it has been proposed that cells are damaged by a direct interaction of the basic MBP with the bilayer lipid membrane [10] , that it modulates enzymatic activity [11] [12] [13] , or that it binds directly to specific receptors at the cell surface [14] . The MBP domain shares weak sequence identity with the C-type lectin (CTL) superfamily, and its crystal structure resembles canonical CTL domains, known from mannose-binding protein, E-selectin, tetranectin, lung surfactant protein, and the CTL domains of CD94 and CD69 [15] . MBP folds into one globular domain supported by two disulfide bonds and consists of two main a-helices and eight bstrands, with the latter forming three antiparallel b-sheets (Fig.  2) . Members of the CTL superfamily generally bind carbohydrate in a calcium-dependent manner, with the binding site formed by conserved acidic calcium ion-ligating residues brought together in the tertiary structure by three extended loops and a b-strand. However, these positions are occupied by basic residues in the putative CTL ligand-binding region of MBP, and it was suggested that natural ligands for MBP include sulfated sugars of the heparan sulfate type [15] . In fact, heparin has previously been found to modulate MBP activity in several experimental setups [12] [13] [14] . Accordingly, based on xray crystallography and surface plasmon resonance experiments, the interaction of MBP with heparin and heparan sulfate GAG, but not other sulfated GAGs [16] , was shown. The binding of cell surface receptors substituted with heparan sulfate GAG could be an important step in the cytotoxic and cytostimulatory mechanism of MBP [16] . Such receptors may mediate the accumulation and oligomerization of MBP, promoting its interaction with phospholipids in the plasma membrane and, thereby, membrane disruption and tissue damage. Alternatively, a heparan sulfate proteoglycan may function as a coreceptor in the delivery of noncytotoxic concentrations of MBP to signaling receptors responsible for the cytostimulatory effects of MBP. It was further proposed that in addition to the neutralizing effect of the acidic residues in the propiece, the GAG of the propiece interacts with the CTL ligand-binding region to inhibit its function [15] .
ProMBP Cell Surface Binding
Because MBP is cytotoxic, its cell surface-binding properties are difficult to study. However, proMBP was found to bind directly to the cell surface, and the binding is, indeed, mediated by a heparan sulfate proteoglycan [17] . It has been proposed in several articles and reviews [15] that the proMBP GAG inhibits cell surface-binding of proMBP. The proMBP cell surfacebinding site is localized in the MBP domain but is outside the CTL ligand-binding region. This binding site is involved in crystal contacts in the asymmetric unit of the MBP crystal, possibly explaining why this binding was not identified in the analysis of MBP crystals soaked with heparin disaccharide [16] . Thus, the CTL site is potentially available for other interactions. Interestingly, a previous study showed that proMBP inhibited, in a dose-responsive manner, basophil histamine release and superoxide anion generation stimulated by MBP [18] , suggesting that proMBP and MBP compete for the same receptor. Peptide-mapping experiments identified two regions involved in the cytotoxic and cytostimulatory actions of MBP [19] . These two regions showed different properties regarding cytotoxicity and stimulation of basophil histamine release. The cytotoxicity of the region, corresponding to residues 123-150 in proMBP (Fig. 1) , was comparable to MBP and markedly higher than that in the second region, contained within the CTL ligand-binding region and corresponding to residues 195-222 in proMBP. In contrast, this region was more effective in stimulating basophil histamine release.
The proMBP Gene
Although all tissues analyzed express human proMBP, the highest expression by far is found in the bone marrow and in the placenta [20, 21] , suggesting specifically controlled gene expression in the developing eosinophil and placenta [22] . The human PRG2 gene encoding proMBP is localized to the centromere of the 11q12 region of chromosome 11. The gene is 3.3 kb and composed of six exons [23, 24] , and the proximal promoter sequence contains a TATA and CCAAT box, a GATA transcriptional factor-binding site, a CCAAT/enhancerbinding protein (C/EBP) site, two Ikaros-2 sites, and a signal transducer and activator of transcription site (STAT) [22] . The primary structure of proMBP is known from humans, mice, rats, and guinea pigs, and it shares 50-65% sequence identity in the MBP domain but low sequence identity in the propiece (Fig. 1) . Curiously, a cDNA encoding a protein, proMBP-2, homologous to proMBP, was isolated from umbilical cord stem cells stimulated with interleukin (IL) 5 [21] , a cytokine that causes eosinophil proliferation, differentiation, and activation [25, 26] . The gene encoding proMBP-2, PRG3, was transcribed at a high level and was the fifth most abundant transcript, corresponding to 1% of the total transcripts isolated from IL5-stimulated umbilical cord stem cells. For comparison, the PRG2 gene was the most abundant and corresponded to 8% of total transcripts [21] . The calculated pI values of the mature human proteins differ by more than 100-fold, with pI values of 11.4 and 8.7 for MBP and MBP-2, respectively. Accordingly, MBP-2 was found to have similar biological activities as MBP but diminished potency [21] . ProMBP homologues have also FIG. 1. Alignment of proMBP and proMBP-2 from human (hproMBP1 and hproMBP2), mouse (mproMBP1 and mproMBP2), rat (only rproMBP1), and guinea pig (gproMBP1 and gproMBP2). Conserved residues are shaded, and cysteines residues are in bold. Disulfide pairings of human proMBP [9] are indicated by connecting lines. Arrows indicate sites in the propiece of proteolytic cleavage during processing in the eosinophils [8] .
been isolated from mice and guinea pigs [27, 28] , but unlike human MBP-2, the mature domains have similar pI and appear to have biological properties similar to those of MBP. Human PRG3 is also located on chromosome 11 in the same region as PRG2. Interestingly, human PRG2 is more identical to murine Prg3 than to human PRG3, suggesting a gene duplication event before the divergence of humans and mice. In contrast to human proMBP, human proMBP-2 mRNA was detected only in bone marrow and not in placenta [21] , and no increase above normal levels of proMBP-2 protein could be detected in pregnancy serum [29] . Similarly, murine proMBP and proMBP-2 are not detectable in mouse placenta or mouse pregnancy plasma at the protein level [28] . All proximal promoter elements of the human PRG2 gene are conserved in the PRG3 gene except for the C/EBP site. Lack of functional conservation of this site may explain the eosinophil-restricted and reduced expression of PRG3 [30] . The reason for the eosinophil-restricted expression of the murine Prg2 and Prg3 genes is unknown.
PROTEINASE INHIBITION BY proMBP
ProMBP was discovered in an attempt to initiate cDNA cloning of PAPPA, when several tryptic peptides generated from PAPPA purified from pregnancy serum were in fact derived from proMBP [4] . Subsequently, PAPPA circulating during pregnancy was demonstrated to be a 2:2 disulfidebonded complex of PAPPA and proMBP (PAPPA/proMBP). PAPPA belongs to the metzincin superfamily of metalloproteinases [31, 32] . The metzincins are traditionally subdivided into four subfamilies-the astacins, the adamalysins (ADAMs), the serralysins, and the matrix metalloproteinases (MMPs)-whereas PAPPA and its homologue PAPPA2 constitute a fifth novel subfamily termed the pappalysins [31] . Known proteolytic substrates of uncomplexed PAPPA are insulin-like growth factor-binding proteins (IGFBPs) 2, 4, and 5, which regulate the bioavailability of the insulin-like growth factors (IGFs). IGF1 and IGF2 are 7.5-kDa peptide hormones with homology to proinsulin. The IGFs function both systemically, as endocrine factors, and locally, in an autocrine and paracrine manner, and targeted disruption of Igf genes in mice have demonstrated that both IGF1 and IGF2 are critical for normal fetal growth [33] . IGF1 is also involved in infertility and impaired postnatal growth [33] , whereas IGF2 has little effect on postnatal growth [34] but functions in the reproductive system, where it controls folliculogenesis, placental development, and fetal growth [35, 36] . IGF actions are mediated by the IGF1 receptor (IGF1R), which is a dimeric transmembrane receptor with tyrosine kinase activity. Ligand binding of IGF1R results in transphosphorylation of the receptor subunits and initiation of downstream signaling cascades [37] . In biological fluids, the vast majority of IGF is bound by members of a family of six homologous IGFBPs (IGFBPs 1-6). The IGFBPs bind the IGFs with similar or higher affinities than the IGF receptors. Thus, the IGFBPs function as regulators of the biological activities of IGF1 and IGF2, primarily by acting as a reservoir of IGFs in the circulation and by modulating the interactions between the IGFs and their receptors at the cellular level in target tissues [38] . Proteolytic cleavage of the IGFBPs is generally believed to be the major mechanism for the regulation of IGF activity [39] . The proteolytic fragments of the IGFBPs have reduced affinity for the IGFs, allowing their interaction with IGF receptors. Thus, IGFBP proteinases, such as PAPPA, most likely regulate the local IGF bioavailability in target tissues. The proteolytic activity of the recombinant PAPPA dimer of 400 kDa is more than 100-fold higher than the PAPPA/ proMBP complex of 500 kDa from pregnancy serum. Furthermore, pregnancy serum was found to contain traces (,1%) of uncomplexed PAPPA with a much higher specific proteolytic activity than the PAPPA/proMBP complex, suggesting that proMBP functions as a proteinase inhibitor in vivo [40] .
Physiological Role of PAPPA
A protease that functions in the local regulation of IGF bioavailability, PAPPA is involved in diverse biological processes involving rapid but controlled growth, such as wound healing, bone remodeling, folliculogenesis, placental development, and atherosclerosis. All tissues analyzed express PAPPA and proMBP [20] . The genes encoding PAPPA and proMBP are some of the most highly expressed in the human placenta [41] , and the levels of circulating PAPPA increases during pregnancy, reaching approximately 25 mg/L at term [5] . PAPPA is implicated in placental growth and function, and low PAPPA levels in the circulation of pregnant women are associated with low birth weight [42] , Down syndrome [43] , Cornelia de Lange syndrome [44] , and miscarriage [45] . In term placenta, PAPPA is localized to the placental septa, anchoring villi, and syncytia of chorionic villi, whereas proMBP is localized to the septa and anchoring villi, as demonstrated by immunohistochemistry [1, 7] . Both placental X cells and syncytiotrophoblasts synthesize PAPPA, whereas proMBP is only synthesized by placental X cells [7] . In humans, IGF2 is abundantly expressed by trophoblasts
The crystal structure of MBP. Shown is a ribbon diagram of human MBP purified from eosinophil granules in standard CTL orientation [122] . The two main a-helices are shown in cyan (Helix 1 and Helix 2), bstrands are shown in magenta, and loops are tinted [15] . The CTL ligandbinding region is normally composed by three extended loops (Loop 1, Loop 3, and Loop 4) and a b-strand (Strand 7). The structure is visualized using PyMOL (http://www.pymol.org).
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invading the maternal decidua [46] , and cell culture experiments have suggested that PAPPA and proMBP may play a key role in syncytiotrophoblast formation and extravillous trophoblast invasion [47, 48] . Also indicating an important role in fetal development, Pappa knockout mice are born at 60% the size of their wild-type littermates [49] . This phenotype is similar to mice with IGF2-null mutations [34] , and IGF2 has been shown to be critical early in embryogenesis for optimal body size [50] . Interestingly, IGF2 is an imprinted gene and only expressed by the maternal allele, but disruption of IGF2 imprinting rescues the dwarf phenotype of the Pappa knockout mouse [51] .
Outside pregnancy, PAPPA expression is particularly stimulated by proinflammatory cytokines. Treatment of human dermal fibroblast with tumor necrosis factor (TNF) and IL1B increased both PAPPA mRNA levels and IGFBP4 proteolytic activity in the medium, while interferon-c treatment markedly inhibited PAPPA expression [52] . These data could suggest a potential role of PAPPA in the acute inflammatory response of wound-healing processes [53] . Indeed, PAPPA expression was induced in healing human skin wounds in dermal granulation tissue within and adjacent to the injury and colocalized with activated macrophages, myofibroblasts, and new blood vessels. In uninjured skin, strong immunohistochemical staining for PAPPA was present in the epidermis, sweat, and sebaceous gland epithelial cells, hair follicles, and blood vessels [54] .
The involvement of IGFs and IGFBPs, and of IGFBPs 2, 4, and 5 in particular, in ovarian folliculogenesis has been extensively studied. Membrana granulosa cells of healthy follicles express PAPPA, and the expression is positively correlated with luteinizing hormone-induced processes of dominant follicle development [55] [56] [57] , suggesting that PAPPA functions in the selection of the dominant follicle by the regulation of IGF bioavailability. Indeed, female PAPPAdeficient mice display reduced fertility and ovarian steroidogenesis [58] . ProMBP has been detected in estrogen-dominant follicular fluid but has not been detected in the medium of cultured granulosa cells or luteinizing granulosa cells [59] , and whether it is associated with PAPPA is unknown.
Expression of PAPPA has been found in both primary cultures of ovarian surface epithelial cells and in uncultured ovarian brushings, suggesting that PAPPA could function to induce the proliferation of ovarian epithelial surface cells after ovulation and subsequent repair of the ovulation-associated wound [60] . Interestingly, proMBP expression is induced upon the transformation of normal ovarian surface epithelial cells to malignant ovarian epithelial cells in a model for ovarian epithelial cancer, resulting in decreased IGFBP4 proteolytic activity [60] . In addition, ovarian epithelial tumor samples, but not uncultured ovarian brushings from healthy individuals, contained measurable proMBP mRNA levels. The physiological relevance of this observation is unclear, but tumor promoters can increase cell differentiation rather than cell proliferation [61] , and higher IGFBP4 levels through the inhibition of PAPPA by proMBP could reflect a more specialized function of the tumor cells. On the other hand, invasive tumor cells could have decreased growth requirements for IGF-1, and high levels of IGFBP4 would limit the growth of the surrounding cells and enhance the invasive properties of the tumor cells.
Expression of PAPPA in human coronary artery smooth muscle cells is also stimulated by TNF and IL1B [62] and also by IL6 [32] , suggesting a mechanism for the regulation of PAPPA expression contributing to the increased IGF1 activity observed in intimal hyperplasia and atherosclerotic plaque development. Curiously, resveratrol, a polyphenol found in the skin of grapes and associated with the beneficial cardiovascular effects of red wine, inhibited TNF-and IL1B-induced PAPPA expression [62] . PAPPA expression is also increased in pig coronary arteries following balloon angioplasty [63] , and similar up-regulation was observed upon vascular injury in mice [52] . Furthermore, intense immunostaining for PAPPA was observed in ruptured and eroded human atherosclerotic plaques in association with activated macrophages and smooth muscle cells [64] . Plaque rupture was accompanied by an increase in plasma levels of the PAPPA dimer [64, 65] . Thus, PAPPA has the characteristics of a potential early diagnostic marker for unstable angina. Importantly, Pappa knockout mice have increased life span [66] and are protected against cardiovascular disease [67] , whereas the development of atherosclerosis is accelerated upon transgenic overexpression of PAPPA in mice [68] .
Both PAPPA and proMBP are also involved in bone formation and homeostasis. TNF and IL1B, in addition to IL4 and TGFB, stimulate PAPPA expression and increase the IGFBP4 proteolytic activity in cultured human osteoblasts [69, 70] . Interestingly, untreated osteoblasts expressed low levels of proMBP, but the proMBP mRNA levels were completely suppressed upon TGFB treatment [70] , suggesting that TGFB can amplify the biological response by both increasing PAPPA expression and decreasing proMBP expression. TGFB and the IGFs belong to a subset of growth factors that are stored in the bone matrix and released during osteoclast resorption to mediate local coupling of bone formation and resorption [71] . The role of PAPPA in the formation of new bone has recently been verified in vivo in two studies describing increased osteoblast proliferation in transgenic mice that overexpress PAPPA in osteoblasts [72] and delayed bone fracture repair in Pappa knockout mice [73] . Interestingly, the treatment of fibroblasts and osteoblasts with phorbol ester tumor promoters and their transformation with simian virus 40 large T antigen resulted in inhibition of IGFBP4 proteolytic activity without a reduction in PAPPA expression [74, 75] . This was later demonstrated to be the result of induced expression of proMBP [76] .
The Inhibitory Mechanism of proMBP
The PAPPA/proMBP complex contains close to 200 cysteine residues. Of the 82 cysteine residues of each PAPPA subunit in the PAPPA/proMBP complex, 78 participate in intramolecular disulfide bonds, whereas one participates in an intersubunit PAPPA/PAPPA disulfide bond and two participate in intermolecular disulfide bonds with proMBP [54] . Mutation of these cysteines in proMBP results in a proMBP variant that is unable to form the covalent PAPPA/proMBP complex and inhibit the proteolytic activity of PAPPA [77] . Thus, the formation of intermolecular proteinase-inhibitor disulfide bonds is required for inhibition of proteolytic activity. Proteinase inhibitors normally function through noncovalent interactions with their target proteinase, either by binding to the active site in a substrate-like manner, by binding adjacent to the active site or to an exosite, or by binding outside the active site causing inhibition through an allosteric mechanism. The serpins and a 2 -macroglobulin form covalent complexes with their target proteinases [78, 79] . To our knowledge, however, an inhibitory mechanism based on the formation of intermolecular proteinase-inhibitor disulfide bonds has not been described previously. Tissue inhibitors of metalloproteinases (TIMPs 1-4) are broad-spectrum endogenous inhibitors of all members of the MMP subfamily of the metzincin superfamily in addition to some members of the ADAM subfamily [80] .
WEYER AND GLERUP
They function by forming a tight, binding, noncovalent 1:1 complex through interactions with both the active site and exosites of the MMPs [81] . Only a few additional endogenous inhibitors have been described for the metzincin metalloproteinases, and proMBP is the first described inhibitor of a member of the pappalysin subfamily. Interestingly, the zymogens of many metzincin metalloproteinases are inhibited by their propeptides through the interaction of a cysteine sidechain sulfur atom with the active-site zinc atom [82] . Several cysteines of proMBP could potentially function in such a cysteine-switch mechanism, but their substitution for serine did not increase the proteolytic activity of the resulting mutant PAPPA/proMBP complex [77] . The inhibitory mechanism of proMBP most likely is based on a combination of steric hindrance and allosteric inhibition. In fact, one of the two PAPPA/proMBP disulfide bonds engages a cysteine located directly in a Lin12-Notch module within the proteolytic domain of PAPPA and, thereby, potentially obstructs a substrate-specificity regulatory unit consisting of three Lin12-Notch modules organized in trans within the active PAPPA dimer [83, 84] .
PAPPA/proMBP Complex Formation
Disulfide bonds are normally inserted into proteins during folding in the endoplasmic reticulum assisted by disulfide isomerases, and because of the oxidizing nature of the extracellular space, disulfide bonds in secreted proteins are considered to be very stable. Still, several examples of regulatory mechanisms involving the reduction or formation of specific disulfide bonds in extracellular proteins are found [85] . The target cysteines in PAPPA are unpaired, whereas the reacting cysteines of proMBP engage in a disulfide bond. However, inspection of the PAPPA/proMBP disulfide structure shows that six cysteine residues of the proMBP subunit and two cysteine residues of the PAPPA subunit change their status from the uncomplexed to the complexed states [9] . Thus, the series of covalent events leading to the final PAPPA/proMBP complex is quite complex. First, the proMBP disulfide bond Cys-51-Cys-169 is broken, exposing the reactive Cys-169, which then forms the first interchain disulfide with the PAPPA proteolytic domain cysteine Cys-652. Second, disruption of the proMBP disulfide Cys-89-Cys-128 is followed by Cys-51, forming the interchain disulfide with the PAPPA proteolytic domain cysteine Cys-381. ProMBP is initially a monomer, but it dimerizes during the process of complex formation through formation of the two interchain bonds, Cys-104-Cys-104 and Cys-107-Cys-107, from two Cys-104-Cys-107 intrachain disulfides [9] . The total redox potential is unchanged upon complex formation as each bond broken is accompanied by another bond formed. Complex formation is dramatically accelerated in a reducing environment, and in vivo, it may involve a specific or a nonspecific catalyst, such as a disulfide reductase or a low-molecular-weight thiol compound. Such a catalyst could function to reduce disulfide bonds that are rendered susceptible as a consequence of an initial noncovalent interaction between PAPPA and proMBP.
Detachment of PAPPA from the Cell Surface
The binding of PAPPA to a heparan sulfate proteoglycan directs its proteolytic activity to the surface of cells [86] , suggesting that surface binding controls PAPPA-mediated IGF release and, consequently, IGF signaling spatially. The surfacebinding site is localized to complement control protein (CCP) modules 3 and 4 in the C-terminal region of PAPPA, which contains five consecutive CCP modules [86, 87] . These modules, originally known from proteins associated with the complement system, are responsible for interactions with GAGs in several other proteins [88, 89] . The PAPPA/proMBP complex does not exhibit cell surface binding, but surface binding can be regained following treatment of the PAPPA/ proMBP complex with heparinase [86] . As mentioned, proMBP is substituted with a heparan sulfate GAG chain [90] , but unlike the formation of another covalent proteinaseinhibitor pair, thrombin-antithrombin-III, which critically depends on the binding of heparin-like GAG, creating a template for proteinase-inhibitor interaction [91, 92] , the proMBP GAG does not mediate the initial recognition of PAPPA. Instead, the recognition of PAPPA by proMBP is based on protein-protein interactions and involves proMBP residues located in the extended Loop 2 and in the loop between Strand 2 and Helix 2 of the MBP domain [93] (Fig. 2) . The covalent PAPPA/proMBP complex is formed at the cell surface by localizing the proMBP GAG in close proximity to CCP modules 3 and 4, allowing it to effectively compete with the PAPPA receptor. Apparently, proMBP also loses affinity for its surface receptor upon complex formation. Cys-169 is located in the loop we identified as part of the proMBP surfacebinding site. As mentioned above, Cys-169 switches from participating in an intramolecular proMBP disulfide bond to forming the first intermolecular PAPPA/proMBP disulfide bond. This could potentially cause a conformational change of the loop, resulting in loss of proMBP surface binding.
Covalent complex formation between the serpins or a 2 -macroglobulin and their target proteinases results in rapid clearance from the circulation [79, 94] . Surprisingly, the halflife of PAPPA and proMBP in complex is increased by severalfold compared to the rapid clearance of the uncomplexed components. The slow clearance of PAPPA/proMBP may therefore reflect an unknown function for the circulating complex, and this observation is potentially interesting in light of the depressed levels of total circulating PAPPA associated with Down syndrome [43] and low birth weight [42] . Hence, distinguishing between both forms of circulating PAPPA (uncomplexed PAPPA vs. PAPPA/proMBP) may be of diagnostic value for pregnancy outcome.
The rapid removal of circulating uncomplexed PAPPA and proMBP could indicate that the PAPPA/proMBP complex in human pregnancy is formed at the surface of placental cells rather than in the circulation. Notably, approximately 1% of PAPPA in pregnancy serum is uncomplexed and proteolytically active [40] . The high clearance rate indicates that the turnover of uncomplexed PAPPA is higher than would be expected from this fraction. Taken together, PAPPA inhibition may be important for the regulation of IGF activity in vivo, and the growth-promoting effect of PAPPA possibly is only properly antagonized by proMBP on cells also expressing the proMBP receptor. It can further be speculated that pathological conditions of altered redox potential, such as placental hypoxia in preeclampsia, may change the balance between complexed and uncomplexed PAPPA and, consequently, IGF signaling.
HIGH-MOLECULAR-WEIGHT AGT
ProMBP circulating during pregnancy exists in a molar excess compared to PAPPA, and some of this was purified and identified as disulfide-bonded 2:2 complexes of proMBP/AGT and 2:2:2 complexes of proMBP/AGT/C3dg [5] . AGT is a prohormone, and proteolytic cleavage of the N-terminal by the aspartyl proteinase renin results in the generation of the decapeptide angiotensin-1 (Ang-1), which is the first and rate-REGULATION OF PROTEOLYSIS BY proMBP limiting step of the renin-angiotensin system (RAS) (Fig. 3 ) [95] . Cells of the liver continuously secrete circulating AGT at concentrations close to the Michaelis constant (K m ) of the reaction [96, 97] . Renin, in turn, is stored in granules of the juxtaglomerular cells in the kidney and is secreted in response to decreased blood volume or sodium levels. Angiotensinconverting enzyme, primarily present in the lung endothelium, further cleaves Ang-1, leading to the generation of the octapeptide angiotensin-2 (Ang-2), the physiologically active component of the system. Ang-2 regulates blood pressure directly by stimulating kidney Ang-2 type 1 receptors (AT-1), thereby modulating renal sodium and water reabsorption, and indirectly by stimulating the production and release of aldosterone from the adrenal glands and by stimulating the sensation of thirst in the central nervous system [98] . The proteins associated with RAS are linked to a number of cardiovascular and renal disorders, in particular hypertension. In contrast to AT-1 receptors that are present in adult cardiovascular tissue, the Ang-2 type 2 receptors are highly expressed during fetal development and may mediate vasodilator responses. In addition to their function in the cardiovascular system, all RAS components are also synthesized locally in numerous organs, and Ang-2 and derived peptides act directly at the cellular level in a paracrine or autocrine manner, influencing processes such as cell growth, proliferation, and apoptosis [99] .
Normally, the majority of AGT circulates as a monomer of approximately 54 kDa, in addition to a minor fraction of higher molecular weight (HMW AGT). The HMW AGT fraction increases in the circulation of women on oral contraceptives (10%) and during pregnancy (16%), and it may become the predominant form in pathological conditions, such as hypertension and preeclampsia [100] [101] [102] . HMW AGT is a major component of the placental-specific RAS and is the predominant form in amniotic fluid and placental extracts, and the increased fraction of circulating HMW AGT is believed to be of placental origin [103, 104] . Although the HMW AGT form was first described 30 years ago, its formation, physiological function, and relation to disease are poorly understood. The HMW AGT fraction has typically been monitored by gel filtration of biological fluids or tissue extracts followed by the incubation of fractions with renin and quantification of the generated Ang-1 by a radioimmunoassay [101] [102] [103] [105] [106] [107] . The molecular weight of the HMW AGT species is in the range of 200-500 kDa, but upon reduction, monomeric AGT is generated, suggesting that it consists of at least one subunit of the AGT monomer covalently linked through disulfide bonds to additional unknown proteins or other AGT molecules [104, 108, 109] .
The presence of proMBP/AGT complexes has been demonstrated in plasma of both normal and pregnant individuals [5, 110] . The complex formation between AGT and proMBP has been studied and was shown to form upon coexpression in mammalian cells and to depend on Cys-232 of AGT [111] . Interestingly, Ang-1 generation by renin from the recombinant AGT/proMBP complex was slower than that from the AGT monomer [111] , rendering proMBP the first example of a natural inhibitor of Ang-1 generation. Ang-1 generation is the first step of RAS, and regulation at this level will consequently affect all endocrine and paracrine functions of Ang-2 and additional peptides derived from Ang-1 (Fig. 3) . HMW AGT complex formation may function as a clearance mechanism for AGT in response to increased Ang-2 signaling. Thus, complex formation of AGT/proMBP/C3dg and subsequent binding and internalization by complement receptor 2 [112] potentially assist in removal of excess AGT. In this way, the increased fraction of circulating HMW AGT associated with hypertension and preeclampsia might be a response to, rather than the cause of, the pathological condition.
The origin of circulating HMW AGT in normal or hypertensive individuals is unknown, but most tissues known to express local RAS also synthesize proMBP [20, 99] . HMW AGT circulating during pregnancy is probably derived from the placental RAS, and AGT is associated with the surface of placental and renal-derived cells [113, 114] . However, proMBP interacts with a cell surface heparan sulfate proteoglycan [17] . Thus, it is tempting to speculate that HMW AGT complex formation operates locally at the surface of cells to regulate the paracrine and autocrine functions of RAS and that its formation could be induced in response to increased Ang-2 signaling. In this view, it is interesting that local C3 production is increased in Ang-2-induced organ damage [115] . Furthermore, it has been speculated that the formation of the PAPPA/proMBP complex and AGT/proMBP complex are competing reactions [48, 116] . As a consequence, increased HMW AGT complex formation in tissues where PAPPA and AGT operate together, such as the cardiovascular system and the reproductive system, could contribute indirectly to the pathophysiology of conditions like hypertension and preeclampsia by increasing the amount of uncomplexed active PAPPA and, hence, IGF signaling (Fig. 4) . Such a natural balance of uncomplexed   FIG. 3 . The renin-angiotensin system (RAS). In response to low blood pressure, the kidneys release the aspartyl proteinase renin. Renin cleaves circulating AGT at a specific site at the N-terminal, releasing the decapeptide Ang-1. Ang-1 is further cleaved by the metalloproteinase angiotensin-converting enzyme (ACE) to the octapeptide Ang-2. Ang-2 causes vasoconstriction and triggers the release of aldosterone from the adrenal gland. Aldosterone causes the kidney to retain sodium and excrete potassium. The components of RAS are also synthesized locally in tissues and Ang-2, and derived peptides act in a paracrine or autocrine manner to influence a number of cellular processes [99] .
and complexed PAPPA and AGT may be further perturbed during hypoxia or oxidative stress.
FUTURE DIRECTIONS
The formation of AGT/proMBP and PAPPA/proMBP are potentially competing reactions, and changes in the concentrations of one of these three components may alter the activity of the other components in systems where AGT, PAPPA, and proMBP operate together in vivo (Fig. 4) . Because both processes likely are critically dependent on the redox potential, this effect may be further amplified in certain pathological conditions. Hence, the increased HMW AGT complex formation associated with pathological conditions, such as hypertension and preeclampsia, could increase IGF signaling indirectly by decreasing the local levels of uncomplexed proMBP and, thereby, contribute to the pathophysiology of these conditions. Further studies are required to manifest the physiological role of proMBP as an inhibitor of proteolysis by PAPPA and of renin-mediated prohormone conversion of AGT. Also, samples from patients with hypertension or preeclampsia should be analyzed for their content of AGT/ proMBP-containing complexes to determine if the composition of HMW AGT under these conditions is similar to what is found in pregnancy serum and male plasma from normal individuals.
The most relevant biological systems for investigating the function of proMBP are the cardiovascular system and the reproductive system, in which both AGT and PAPPA have well-documented roles. However, studies of proMBP function in vivo are hampered by the lack of a suitable animal model. For example, neither PAPPA nor proMBP are expressed at high levels in the mouse placenta, nor does an increase occur in the amount of circulating PAPPA during mouse pregnancy [117] . Furthermore, the AGT cysteine responsible for AGT/ proMBP intermolecular disulfide bond formation is absent from the primary structure of mouse AGT, suggesting that AGT/proMBP complex formation does not occur in mice.
Transgenic rats and mice overexpressing human AGT and human renin have been constructed [118, 119] . The transgenic mouse model reported by Merrill et al. [118] is chronically hypertensive. However, the transgenic mouse model reported by Takimoto et al. [119] displayed a transient elevation in blood pressure in late pregnancy; blood pressure returned to normal levels after delivery of the pups [119] . In contrast, the transgenic rat model constructed by Luft et al. [120] develops moderately severe hypertension, and the rats die early because of cardiac and renal damage. Interestingly, organ damage is reduced upon treatment with the rennin-inhibitor aliskiren [121] . A proof-of-concept experiment could be the treatment of one of these animal models with recombinant proMBP. The probability for success of such an experiment is increased by the utilization of a proMBP variant with increased ability to form the PAPPA/proMBP complex and reduced clearance rate. Thus, the substitution of Cys-51 combined with the mutation of residues involved in proMBP cell surface binding would generate a proMBP variant with increased ability to form the AGT/proMBP complex, in addition to better pharmacokinetic properties. As mentioned, overexpression of PAPPA in mice results in accelerated development of atherosclerosis [68] , and similar treatment of such a mouse model with the same proMBP variant would sweep the vascular wall for PAPPA and potentially ameliorate the pathological condition. 
